Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Beumont

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|February 19, 2005
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patientsYves Lévy, Hanne Gahéry-Ségard, Christine Durier, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2017
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir RegimenStefan Bourgeois, Yves Horsmans, Frederik Nevens, et al.
Journal of Medicinal Chemistry|January 23, 2014
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitorÅsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
BMC Infectious Diseases|June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studyEdward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|February 19, 2005
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patientsYves Lévy, Hanne Gahéry-Ségard, Christine Durier, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2017
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir RegimenStefan Bourgeois, Yves Horsmans, Frederik Nevens, et al.
Journal of Medicinal Chemistry|January 23, 2014
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitorÅsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
BMC Infectious Diseases|June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studyEdward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|January 17, 2013
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failureStanislas Pol, Jeroen Aerssens, Stefan Zeuzem, et al.
Pageof 5